DosEmi Study Protocol: a Phase IV, Multicentre, Open-Label, Crossover Study to Evaluate Non-Inferiority of Pharmacokinetic-Guided Reduced Dosing Compared with Conventional Dosing of Emicizumab in People with Haemophilia A
BMJ Open（2023）
Key words
bleeding disorders & coagulopathies,epidemiologic studies,paediatrics,clinical pharmacology,clinical trials
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined